Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.62
-0.01000-0.61%
At close: -
$1.65
0.031.85%
After Hours: 6:45 PM EDT
Comments
Loading...
ProQR Therapeutics Analyst Ratings and Price Targets | NASDAQ:PRQR | Benzinga
ProQR Therapeutics NV has a consensus price target of $7.72 based on the ratings of 9 analysts. The high is $14 issued by Raymond James on October 29, 2024. The low is $2 issued by Citigroup on April 18, 2024. The 3 most-recent analyst ratings were released by Oppenheimer, Evercore ISI Group, and Chardan Capital on May 13, 2025, April 29, 2025, and March 14, 2025, respectively. With an average price target of $6 between Oppenheimer, Evercore ISI Group, and Chardan Capital, there's an implied 263.64% upside for ProQR Therapeutics NV from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Evercore ISI Group
Chardan Capital
HC Wainwright & Co.
Jones Trading
1calculated from analyst ratings
Analyst Ratings for ProQR Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2025 | Buy Now | 445.45% | Oppenheimer | Andreas Argyrides70% | $15 → $9 | Maintains | Outperform | Get Alert |
| 04/29/2025 | Buy Now | 203.03% | Evercore ISI Group | Gavin Clark-Gartner36% | → $5 | Initiates | → Outperform | Get Alert |
| 03/14/2025 | Buy Now | 142.42% | Chardan Capital | Keay Nakae54% | $4 → $4 | Maintains | Buy | Get Alert |
| 03/14/2025 | Buy Now | 627.27% | HC Wainwright & Co. | Andrew Fein52% | $10 → $12 | Maintains | Buy | Get Alert |
| 02/12/2025 | Buy Now | 566.67% | Jones Trading | Catherine Novack31% | → $11 | Initiates | → Buy | Get Alert |
| 12/12/2024 | Buy Now | 384.85% | JMP Securities | Jonathan Wolleben69% | $8 → $8 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/12/2024 | Buy Now | 142.42% | Chardan Capital | Keay Nakae54% | $4 → $4 | Maintains | Buy | Get Alert |
| 12/12/2024 | Buy Now | 506.06% | HC Wainwright & Co. | Andrew Fein52% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2024 | Buy Now | 506.06% | HC Wainwright & Co. | Andrew Fein52% | $5 → $10 | Maintains | Buy | Get Alert |
| 10/29/2024 | Buy Now | 748.48% | Raymond James | Steven Seedhouse7% | $6 → $14 | Upgrade | Outperform → Strong Buy | Get Alert |
| 05/10/2024 | Buy Now | 203.03% | HC Wainwright & Co. | Andrew Fein52% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 51.52% | Chardan Capital | Keay Nakae54% | $2.5 → $2.5 | Maintains | Buy | Get Alert |
| 04/18/2024 | Buy Now | 21.21% | Citigroup | Yigal Nochomovitz53% | $1.8 → $2 | Maintains | Neutral | Get Alert |
| 03/14/2024 | Buy Now | 203.03% | HC Wainwright & Co. | Andrew Fein52% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | 51.52% | Chardan Capital | Keay Nakae54% | $2 → $2.5 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 142.42% | Raymond James | Steven Seedhouse7% | $5 → $4 | Maintains | Outperform | Get Alert |
| 11/08/2023 | Buy Now | 21.21% | Chardan Capital | Keay Nakae54% | → $2 | Upgrade | Neutral → Buy | Get Alert |
| 09/18/2023 | Buy Now | 9.09% | Citigroup | Yigal Nochomovitz53% | $2.1 → $1.8 | Maintains | Neutral | Get Alert |
| 08/07/2023 | Buy Now | 203.03% | HC Wainwright & Co. | Andrew Fein52% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | 21.21% | Chardan Capital | Keay Nakae54% | → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 05/26/2023 | Buy Now | 27.27% | Citigroup | Yigal Nochomovitz53% | $2.25 → $2.1 | Maintains | Neutral | Get Alert |
| 05/17/2023 | Buy Now | 172.73% | Cantor Fitzgerald | Jennifer Kim45% | $5 → $4.5 | Maintains | Overweight | Get Alert |
| 05/17/2023 | Buy Now | 263.64% | JMP Securities | Jonathan Wolleben69% | → $6 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/17/2023 | Buy Now | 203.03% | HC Wainwright & Co. | Andrew Fein52% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/30/2023 | Buy Now | 263.64% | JMP Securities | Jonathan Wolleben69% | → $6 | Reiterates | → Market Outperform | Get Alert |
| 03/30/2023 | Buy Now | 203.03% | HC Wainwright & Co. | Andrew Fein52% | $1.5 → $5 | Maintains | Buy | Get Alert |
| 12/23/2022 | Buy Now | 203.03% | Raymond James | Steven Seedhouse7% | $2 → $5 | Maintains | Outperform | Get Alert |
| 12/22/2022 | Buy Now | 203.03% | Cantor Fitzgerald | Jennifer Kim45% | $0.8 → $5 | Upgrade | Neutral → Overweight | Get Alert |
| 08/15/2022 | Buy Now | -9.09% | HC Wainwright & Co. | Andrew Fein52% | $2 → $1.5 | Maintains | Buy | Get Alert |
| 08/12/2022 | Buy Now | — | Chardan Capital | Keay Nakae54% | — | Downgrade | Buy → Neutral | Get Alert |
| 08/12/2022 | Buy Now | 21.21% | Raymond James | Steven Seedhouse7% | → $2 | Upgrade | Market Perform → Outperform | Get Alert |
FAQ
What is the target price for ProQR Therapeutics (PRQR) stock?
The latest price target for ProQR Therapeutics (NASDAQ:PRQR) was reported by Oppenheimer on May 13, 2025. The analyst firm set a price target for $9.00 expecting PRQR to rise to within 12 months (a possible 445.45% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ProQR Therapeutics (PRQR)?
The latest analyst rating for ProQR Therapeutics (NASDAQ:PRQR) was provided by Oppenheimer, and ProQR Therapeutics maintained their outperform rating.
When was the last upgrade for ProQR Therapeutics (PRQR)?
The last upgrade for ProQR Therapeutics NV happened on October 29, 2024 when Raymond James raised their price target to $14. Raymond James previously had an outperform for ProQR Therapeutics NV.
When was the last downgrade for ProQR Therapeutics (PRQR)?
The last downgrade for ProQR Therapeutics NV happened on August 12, 2022 when Chardan Capital changed their price target from N/A to N/A for ProQR Therapeutics NV.
When is the next analyst rating going to be posted or updated for ProQR Therapeutics (PRQR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on May 13, 2025 so you should expect the next rating to be made available sometime around May 13, 2026.
Is the Analyst Rating ProQR Therapeutics (PRQR) correct?
While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a maintained with a price target of $15.00 to $9.00. The current price ProQR Therapeutics (PRQR) is trading at is $1.65, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
